Lantern Pharma Q3 2025 Webcast and AI Platform Developments FAQ
TL;DR
Lantern Pharma's AI-driven cancer therapies offer investors potential advantage through its $15 billion market pipeline and upcoming Q3 results webcast on November 13, 2025.
Lantern Pharma uses its RADR platform with 200+ ML algorithms and 200 billion data points to systematically accelerate oncology drug discovery and clinical trial progress.
Lantern Pharma's AI-driven cancer therapies aim to provide life-changing treatments to hundreds of thousands of patients worldwide through faster, more effective drug development.
Lantern Pharma's RADR platform analyzes 200 billion oncology data points to discover cancer therapies, with management discussing progress in their November 13 webcast.
Found this article helpful?
Share it with your network and spread the knowledge!
The webcast will review Lantern Pharma's third-quarter 2025 operating and financial results, discuss clinical trial progress, and provide updates on the company's AI and machine learning initiatives.
The webcast will be held on Thursday, November 13, 2025 at 9 a.m. ET (6 a.m. PT) and will be accessible online.
President and CEO Panna Sharma and other members of the management team will be presenting and discussing the company's quarterly performance and developments.
RADR is Lantern Pharma's proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and 200+ advanced ML algorithms to accelerate cancer drug discovery and development.
Lantern Pharma is developing targeted cancer therapies that span multiple cancer indications including both solid tumors and blood cancers, plus an antibody-drug conjugate (ADC) program.
The company has a Phase 2 clinical program and multiple Phase 1 clinical trials currently underway in their development pipeline.
Lantern Pharma's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.
The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN, and the full press release can be viewed at https://ibn.fm/BMDrb.
Lantern Pharma's AI platform transforms the cost, pace, and timeline of oncology drug discovery and development, helping to solve billion-dollar problems in oncology while potentially providing life-changing therapies to hundreds of thousands of cancer patients worldwide.
AINewsWire is a specialized communications platform focused on AI advancements that published this announcement and provides distribution services through the Investor Brand Network, including wire solutions, media syndication, and social media distribution.
Curated from InvestorBrandNetwork (IBN)
